Literature DB >> 25339361

Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13.

Suzan Imren1, Michael Heuser2, Maura Gasparetto3, Philip A Beer1, Gudmundur L Norddahl1, Ping Xiang1, Ling Chen1, Tobias Berg4, Garrett W Rhyasen1, Patricia Rosten1, Gyeongsin Park5, Yeonsook Moon6, Andrew P Weng1, Connie J Eaves1, R Keith Humphries7.   

Abstract

Leukemic transformation of human cells is a complex process. Here we show that forced expression of MN1 in primitive human cord blood cells maintained on stromal cells in vitro induces a transient, but not serially transplantable, myeloproliferation in engrafted mice. However, cotransduction of an activated HOX gene (NUP98HOXD13) with MN1 induces a serially transplantable acute myeloid leukemia (AML). Further characterization of the leukemic cells generated from the dually transduced cells showed the activation of stem cell gene expression signatures also found in primary human AML. These findings show a new forward genetic model of human leukemogenesis and further highlight the relevance of homeobox transcription factors in the transformation process.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339361      PMCID: PMC4256911          DOI: 10.1182/blood-2014-04-564666

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Factors influencing the titer and infectivity of lentiviral vectors.

Authors:  Aaron C Logan; Sarah J Nightingale; Dennis L Haas; Gerald J Cho; Karen A Pepper; Donald B Kohn
Journal:  Hum Gene Ther       Date:  2004-10       Impact factor: 5.695

2.  High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.

Authors:  Michael Heuser; Gernot Beutel; Juergen Krauter; Konstanze Döhner; Nils von Neuhoff; Brigitte Schlegelberger; Arnold Ganser
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

3.  Global gene expression profile of human cord blood-derived CD133+ cells.

Authors:  Taina Jaatinen; Heidi Hemmoranta; Sampsa Hautaniemi; Jari Niemi; Daniel Nicorici; Jarmo Laine; Olli Yli-Harja; Jukka Partanen
Journal:  Stem Cells       Date:  2005-10-06       Impact factor: 6.277

4.  Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal.

Authors:  Michael Heuser; Laura M Sly; Bob Argiropoulos; Florian Kuchenbauer; Courteney Lai; Andrew Weng; Malina Leung; Grace Lin; Christy Brookes; Stephen Fung; Peter J Valk; Ruud Delwel; Bob Löwenberg; Gerald Krystal; R Keith Humphries
Journal:  Blood       Date:  2009-08-10       Impact factor: 22.113

5.  Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells.

Authors:  H Gal; N Amariglio; L Trakhtenbrot; J Jacob-Hirsh; O Margalit; A Avigdor; A Nagler; S Tavor; L Ein-Dor; T Lapidot; E Domany; G Rechavi; D Givol
Journal:  Leukemia       Date:  2006-10-12       Impact factor: 11.528

6.  Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation.

Authors:  Sigal Tavor; Dorothy J Park; Sigal Gery; Peter T Vuong; Adrian F Gombart; H Phillip Koeffler
Journal:  J Biol Chem       Date:  2003-09-29       Impact factor: 5.157

Review 7.  MLL translocations, histone modifications and leukaemia stem-cell development.

Authors:  Andrei V Krivtsov; Scott A Armstrong
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

8.  Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.

Authors:  Junping Wei; Mark Wunderlich; Catherine Fox; Sara Alvarez; Juan C Cigudosa; Jamie S Wilhelm; Yi Zheng; Jose A Cancelas; Yi Gu; Michael Jansen; Jorge F Dimartino; James C Mulloy
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

9.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

Authors:  Maria E Figueroa; Sanne Lugthart; Yushan Li; Claudia Erpelinck-Verschueren; Xutao Deng; Paul J Christos; Elizabeth Schifano; James Booth; Wim van Putten; Lucy Skrabanek; Fabien Campagne; Madhu Mazumdar; John M Greally; Peter J M Valk; Bob Löwenberg; Ruud Delwel; Ari Melnick
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

10.  Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia.

Authors:  T Liu; D Jankovic; L Brault; S Ehret; F Baty; V Stavropoulou; V Rossi; A Biondi; J Schwaller
Journal:  Leukemia       Date:  2010-01-14       Impact factor: 11.528

View more
  11 in total

1.  MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.

Authors:  Simone S Riedel; Jessica N Haladyna; Matthew Bezzant; Brett Stevens; Daniel A Pollyea; Amit U Sinha; Scott A Armstrong; Qi Wei; Roy M Pollock; Scott R Daigle; Craig T Jordan; Patricia Ernst; Tobias Neff; Kathrin M Bernt
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

2.  Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities.

Authors:  Sophie Cardin; Mélanie Bilodeau; Mathieu Roussy; Léo Aubert; Thomas Milan; Loubna Jouan; Alexandre Rouette; Louise Laramée; Patrick Gendron; Jean Duchaine; Hélène Decaluwe; Jean-François Spinella; Stéphanie Mourad; Françoise Couture; Daniel Sinnett; Élie Haddad; Josette-Renée Landry; Jing Ma; R Keith Humphries; Philippe P Roux; Josée Hébert; Tanja A Gruber; Brian T Wilhelm; Sonia Cellot
Journal:  Blood Adv       Date:  2019-11-12

3.  Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.

Authors:  K Nowek; S M Sun; M K Dijkstra; L Bullinger; H Döhner; S J Erkeland; B Löwenberg; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2015-10-14       Impact factor: 11.528

Review 4.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

5.  UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.

Authors:  Ismael Samudio; Katayoun Rezvani; Hila Shaim; Elyse Hofs; Mor Ngom; Luke Bu; Guoyu Liu; Jason T C Lee; Suzan Imren; Vivian Lam; Grace F T Poon; Maryam Ghaedi; Fumio Takei; Keith Humphries; William Jia; Gerald Krystal
Journal:  Blood       Date:  2016-03-03       Impact factor: 22.113

6.  Lentiviral Fluorescent Genetic Barcoding for Multiplex Fate Tracking of Leukemic Cells.

Authors:  Tobias Maetzig; Jens Ruschmann; Lea Sanchez Milde; Courteney K Lai; Niklas von Krosigk; R Keith Humphries
Journal:  Mol Ther Methods Clin Dev       Date:  2017-06-01       Impact factor: 6.698

Review 7.  Modeling the process of human tumorigenesis.

Authors:  Sneha Balani; Long V Nguyen; Connie J Eaves
Journal:  Nat Commun       Date:  2017-05-25       Impact factor: 14.919

8.  Transforming activities of the NUP98-KMT2A fusion gene associated with myelodysplasia and acute myeloid leukemia.

Authors:  James N Fisher; Angeliki Thanasopoulou; Sabine Juge; Alexandar Tzankov; Frederik O Bagger; Max A Mendez; Antoine H F M Peters; Juerg Schwaller
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

9.  Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.

Authors:  Arnold Kloos; Konstantinos Mintzas; Lina Winckler; Razif Gabdoulline; Yasmine Alwie; Nidhi Jyotsana; Nadine Kattre; Renate Schottmann; Michaela Scherr; Charu Gupta; Felix F Adams; Adrian Schwarzer; Dirk Heckl; Axel Schambach; Suzan Imren; R Keith Humphries; Arnold Ganser; Felicitas Thol; Michael Heuser
Journal:  Leukemia       Date:  2020-06-24       Impact factor: 11.528

10.  Meis2 as a critical player in MN1-induced leukemia.

Authors:  C K Lai; G L Norddahl; T Maetzig; P Rosten; T Lohr; L Sanchez Milde; N von Krosigk; T R Docking; M Heuser; A Karsan; R K Humphries
Journal:  Blood Cancer J       Date:  2017-09-29       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.